Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
Loading...
Embargo End Date
ICR Authors
Authors
Gleeson, M
Hawkes, EA
Cunningham, D
Chadwick, N
Counsell, N
Lawrie, A
Jack, A
Smith, P
Mouncey, P
Pocock, C
Ardeshna, KM
Radford, J
McMillan, A
Davies, J
Turner, D
Kruger, A
Johnson, PWM
Gambell, J
Linch, D
Hawkes, EA
Cunningham, D
Chadwick, N
Counsell, N
Lawrie, A
Jack, A
Smith, P
Mouncey, P
Pocock, C
Ardeshna, KM
Radford, J
McMillan, A
Davies, J
Turner, D
Kruger, A
Johnson, PWM
Gambell, J
Linch, D
Document Type
Journal Article
Date
2016-11
Date Accepted
2016-06-22
Abstract
We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.
Citation
British journal of haematology, 2016, 175 (4), pp. 668 - 672
Rights
Source Title
Publisher
ISSN
0007-1048
eISSN
1365-2141
Collections
Research Team
Medicine (RMH Smith Cunningham)